REGN analyst scorecard · Regeneron Pharmaceuticals
74 rating actions on REGN in the last 12 months. Of 96 price targets that resolved, 24 were reached while they stood, 68 were replaced by the same firm first, and 4 fell short at their deadline. Ratings: 61% Buy-type, 38% Hold-type, 1% Sell-type. Consensus target $869, 7% above the last close.
Checked through 2026-10-29 · last close $812.89 (2026-10-29). Rebuilt every morning.
Targets reached while they stood
25.0% 24 of 96
Replaced before the deadline
70.8%
Short at the deadline
4.2%
Ratings vs XLV
7 of 15
Buy / Hold / Sell, 12 mo
61 / 38 / 1%
Consensus target
$869 +6.9%
What the Holds say: 28 Hold-type ratings on REGN in the last 12 months carried a median target +3% from the price on the day; 29% sat below it.
The 4 upgrades on REGN came after an average +3.5% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Overweight | 2026-07-31 | $795 | 3 | 0 | 3 | 0 of 1 |
| Guggenheim | Buy | 2026-08-03 | $1030 | 0 | 6 | 6 | 1 of 1 |
| Truist Securities | Buy | 2026-10-07 | $780 | 2 | 8 | 10 | 0 of 1 |
| Citigroup | Neutral | 2026-08-03 | $740 | 2 | 6 | 8 | 1 of 1 |
| Leerink Partners | Market Perform | 2026-08-17 | $824 | 0 | 0 | 1 | 1 of 1 |
| Benchmark | Buy | 2026-07-07 | $185 | — | — | 0 | — |
| Oppenheimer | Outperform | 2026-02-02 | $865 | 0 | 4 | 4 | 0 of 1 |
| Evercore ISI Group | Outperform | 2026-01-22 | $875 | — | — | 0 | — |
| HSBC | Buy | 2026-09-10 | $920 | 0 | 2 | 2 | — |
| Morgan Stanley | Equal-Weight | 2026-10-07 | $779 | 2 | 8 | 10 | — |
| Canaccord Genuity | Buy | 2026-10-28 | $922 | 0 | 6 | 6 | 1 of 1 |
| Piper Sandler | Overweight | 2026-10-19 | $865 | 0 | 3 | 4 | 0 of 1 |
| JPMorgan | Overweight | 2026-10-06 | $950 | 2 | 3 | 5 | 1 of 1 |
| BMO Capital | Outperform | 2026-05-18 | $730 | 2 | 4 | 6 | 0 of 1 |
| Barclays | Overweight | 2026-04-30 | $917 | 0 | 1 | 2 | 0 of 1 |
| RBC Capital | Sector Perform | 2026-10-08 | $810 | 2 | 7 | 9 | — |
| Wells Fargo | Equal-Weight | 2026-07-31 | $750 | 4 | 4 | 8 | — |
| TD Cowen | Buy | 2026-10-21 | $980 | 0 | 1 | 1 | — |
| UBS | Buy | 2026-10-15 | $978 | 2 | 1 | 3 | — |
| Bank of America | Buy | 2026-01-07 | $860 | — | — | 0 | — |
| Jefferies | Buy | 2026-10-01 | $930 | 1 | 0 | 1 | 1 of 1 |
| Argus Research | Buy | 2026-10-01 | $850 | — | — | 0 | — |
| Bernstein | Outperform | 2026-04-08 | $921 | 1 | 1 | 2 | 0 of 1 |
| Scotiabank | Sector Perform | 2025-11-24 | $770 | — | — | 0 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor REGN carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | Canaccord Genuity | Buy | maintained | $813.27 | $922 | running to 2027-10-28 | +8.1% |
| 2026-10-21 | TD Cowen | Buy | maintained | $805.67 | $980 | running to 2027-10-21 | +0.9% |
| 2026-10-19 | Piper Sandler | Overweight | maintained | $782.04 | $865 | running to 2027-10-19 | -0.4% |
| 2026-10-15 | UBS | Neutral → Buy | upgrade | $796.34 | $978 | running to 2027-10-15 | +2.9% |
| 2026-10-08 | RBC Capital | Sector Perform | maintained | $739.57 | $810 | reached 2026-10-22 | -8.7% |
| 2026-10-07 | Truist Securities | Buy | maintained | $742.12 | $780 | reached 2026-10-15 | -10.3% |
| 2026-10-07 | Morgan Stanley | Equal-Weight | maintained | $742.12 | $779 | within 5% of price when set | -10.3% |
| 2026-10-06 | JPMorgan | Overweight | maintained | $738.72 | $950 | running to 2027-10-06 | -10.8% |
| 2026-10-01 | Jefferies | Buy | maintained | $734.81 | $930 | running to 2027-10-01 | -10.8% |
| 2026-10-01 | Argus Research | Hold → Buy | upgrade | $734.81 | $850 | running to 2027-10-01 | -10.8% |
| 2026-09-29 | RBC Capital | Sector Perform | reiterated | $750.51 | $737 | within 5% of price when set | -5.5% |
| 2026-09-10 | HSBC | Buy | maintained | $793.26 | $920 | running to 2027-09-10 | -0.5% |
| 2026-08-17 | Leerink Partners | Market Perform | maintained | $805.93 | $824 | within 5% of price when set | +19.1% |
| 2026-08-03 | Citigroup | Neutral | maintained | $759.24 | $740 | within 5% of price when set | +16.0% |
| 2026-08-03 | Guggenheim | Buy | maintained | $759.24 | $1030 | running to 2027-08-03 | +16.0% |
| 2026-07-31 | RBC Capital | Sector Perform | maintained | $762.63 | $737 | within 5% of price when set | +22.1% |
| 2026-07-31 | Morgan Stanley | Equal-Weight | maintained | $762.63 | $758 | within 5% of price when set | +22.1% |
| 2026-07-31 | Cantor Fitzgerald | Overweight | maintained | $762.63 | $795 | within 5% of price when set | +22.1% |
| 2026-07-31 | Wells Fargo | Equal-Weight | maintained | $762.63 | $750 | within 5% of price when set | +22.1% |
| 2026-07-31 | Truist Securities | Buy | maintained | $762.63 | $772 | within 5% of price when set | +22.1% |
| 2026-07-21 | Guggenheim | Buy | maintained | $675.19 | $1000 | replaced 2026-08-03, new $1030 | +10.7% |
| 2026-07-09 | Piper Sandler | Overweight | maintained | $667.95 | $854 | replaced 2026-10-19, new $865 | +8.4% |
| 2026-07-08 | Morgan Stanley | Equal-Weight | maintained | $662.88 | $730 | reached 2026-07-30 | +8.4% |
| 2026-07-07 | RBC Capital | Sector Perform | maintained | $676.23 | $696 | within 5% of price when set | +6.4% |
| 2026-07-07 | Truist Securities | Buy | maintained | $676.23 | $769 | replaced 2026-07-31, new $772 | +6.4% |
| 2026-07-07 | Benchmark | Hold → Buy | upgrade | $676.23 | $185 | — | +6.4% |
| 2026-07-06 | HSBC | Buy | maintained | $649.81 | $880 | replaced 2026-09-10, new $920 | +2.3% |
| 2026-07-06 | Cantor Fitzgerald | Overweight | maintained | $649.81 | $750 | reached 2026-07-31 | +2.3% |
| 2026-05-19 | Canaccord Genuity | Buy | maintained | $630.30 | $875 | replaced 2026-10-28, new $922 | -16.0% |
| 2026-05-18 | BMO Capital | Outperform | maintained | $629.68 | $730 | reached 2026-07-30 | -16.1% |
| 2026-05-18 | Truist Securities | Buy | maintained | $629.68 | $778 | replaced 2026-07-07, new $769 | -16.1% |
| 2026-05-18 | JPMorgan | Overweight | maintained | $629.68 | $850 | reached 2026-09-02 | -16.1% |
| 2026-05-18 | Piper Sandler | Overweight | maintained | $629.68 | $855 | replaced 2026-07-09, new $854 | -16.1% |
| 2026-05-18 | Wells Fargo | Equal-Weight | maintained | $629.68 | $700 | reached 2026-07-30 | -16.1% |
| 2026-05-18 | RBC Capital | Sector Perform | maintained | $629.68 | $707 | replaced 2026-07-07, new $696 | -16.1% |
| 2026-05-18 | Citigroup | Buy → Neutral | downgrade | $629.68 | $700 | reached 2026-07-30 | -16.1% |
| 2026-05-18 | Leerink Partners | Outperform → Market Perform | downgrade | $629.68 | $641 | within 5% of price when set | -16.1% |
| 2026-05-01 | Guggenheim | Buy | maintained | $701.42 | $995 | replaced 2026-07-21, new $1000 | -9.8% |
| 2026-04-30 | RBC Capital | Sector Perform | maintained | $707.06 | $762 | replaced 2026-05-18, new $707 | -8.5% |
| 2026-04-30 | Barclays | Overweight | maintained | $707.06 | $917 | running to 2027-04-30 | -8.5% |
| 2026-04-30 | Truist Securities | Buy | maintained | $707.06 | $796 | replaced 2026-05-18, new $778 | -8.5% |
| 2026-04-30 | Wells Fargo | Equal-Weight | maintained | $707.06 | $800 | replaced 2026-05-18, new $700 | -8.5% |
| 2026-04-23 | TD Cowen | Buy | maintained | $766.02 | $960 | replaced 2026-10-21, new $980 | +3.3% |
| 2026-04-23 | Cantor Fitzgerald | Overweight | reiterated | $766.02 | $800 | within 5% of price when set | +3.3% |
| 2026-04-10 | Morgan Stanley | Equal-Weight | maintained | $748.87 | $796 | replaced 2026-07-08, new $730 | -3.3% |
| 2026-04-08 | Bernstein | Outperform | maintained | $775.53 | $921 | running to 2027-04-08 | -0.8% |
| 2026-03-31 | Truist Securities | Buy | maintained | $772.64 | $801 | within 5% of price when set | -1.2% |
| 2026-03-06 | Barclays | Overweight | initiated | $759.86 | $923 | replaced 2026-04-30, new $917 | -2.0% |
| 2026-03-02 | RBC Capital | Sector Perform | maintained | $790.81 | $765 | within 5% of price when set | +6.7% |
| 2026-02-09 | Guggenheim | Buy | maintained | $780.28 | $975 | replaced 2026-05-01, new $995 | -2.0% |
| 2026-02-02 | JPMorgan | Overweight | maintained | $755.02 | $950 | replaced 2026-05-18, new $850 | -2.7% |
| 2026-02-02 | Oppenheimer | Outperform | reiterated | $755.02 | $865 | running to 2027-02-02 | -2.7% |
| 2026-02-02 | Morgan Stanley | Equal-Weight | maintained | $755.02 | $769 | within 5% of price when set | -2.7% |
| 2026-02-02 | Wells Fargo | Equal-Weight | maintained | $755.02 | $800 | reached 2026-02-13 | -2.7% |
| 2026-02-02 | Cantor Fitzgerald | Overweight | maintained | $755.02 | $800 | reached 2026-02-13 | -2.7% |
| 2026-02-02 | Truist Securities | Buy | maintained | $755.02 | $818 | replaced 2026-03-31, new $801 | -2.7% |
| 2026-01-22 | Evercore ISI Group | Outperform | maintained | $755.51 | $875 | running to 2027-01-22 | -3.8% |
| 2026-01-08 | Truist Securities | Buy | maintained | $801.01 | $820 | within 5% of price when set | +15.7% |
| 2026-01-07 | Bank of America | Underperform → Buy | upgrade | $812.27 | $860 | running to 2027-01-07 | +15.5% |
| 2025-12-12 | Morgan Stanley | Equal-Weight | maintained | $741.29 | $768 | within 5% of price when set | +8.7% |
| 2025-12-10 | Wells Fargo | Equal-Weight | maintained | $726.21 | $745 | within 5% of price when set | +10.9% |
| 2025-12-04 | Canaccord Genuity | Buy | maintained | $722.80 | $1057 | replaced 2026-05-19, new $875 | +15.1% |
| 2025-12-04 | BMO Capital | Outperform | maintained | $722.80 | $850 | replaced 2026-05-18, new $730 | +15.1% |
| 2025-12-03 | Morgan Stanley | Overweight → Equal-Weight | downgrade | $723.67 | $767 | replaced 2025-12-12, new $768 | +12.7% |
| 2025-11-24 | Scotiabank | Sector Perform | maintained | $761.45 | $770 | within 5% of price when set | — |
| 2025-11-24 | HSBC | Buy | initiated | $761.45 | $890 | replaced 2026-07-06, new $880 | — |
| 2025-11-20 | Wells Fargo | Equal-Weight | maintained | $737.00 | $700 | reached 2025-12-09 | — |
| 2025-11-07 | UBS | Neutral | maintained | $657.53 | $660 | within 5% of price when set | — |
| 2025-10-29 | Citigroup | Buy | maintained | $652.91 | $700 | reached 2025-11-17 | — |
| 2025-10-29 | RBC Capital | Sector Perform | maintained | $652.91 | $708 | reached 2025-11-18 | — |
| 2025-10-29 | Wells Fargo | Equal-Weight | maintained | $652.91 | $615 | replaced 2025-11-20, new $700 | — |
| 2025-10-29 | Cantor Fitzgerald | Overweight | maintained | $652.91 | $740 | reached 2025-11-21 | — |
| 2025-10-29 | Guggenheim | Buy | maintained | $652.91 | $865 | replaced 2026-02-09, new $975 | — |
| 2025-10-29 | Bank of America | Underperform | maintained | $652.91 | $627 | within 5% of price when set | — |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.